TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04971187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT06013826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
Study: NCT06548997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 5 μg/kg-maximum tolerated dose (MTD), single dose or two doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study: NCT05037123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous ketamine infusion
Description: Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + Saline
Description: Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
Study: NCT04901286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: Cycling in a lab environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Non-Immersive Virtual Reality
Description: Cycling with an environment simulated by non-immersive virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Immersive Virtual Reality
Description: Cycling with an environment simulated by immersive virtual reality
Study: NCT06086548

Intervention type: OTHER
Intervention: metabolomic on plasma sample
Description: metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling

Intervention type: OTHER
Intervention: metabolomic on plasma sample
Description: metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
Study: NCT04917185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture
Description: Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Study: NCT05473442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQU-001
Description: 20 mg pills of EQU-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQU-001
Description: 20 mg pills of EQU-001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 20 mg matching placebo pills
Study: NCT05472532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient sampling.
Description: One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors
Study: NCT06046807

Intervention type: OTHER
Intervention: Phone call
Description: This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)

Intervention type: OTHER
Intervention: Phone call
Description: This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
Study: NCT05473442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: 20 mg matching placebo pills
Study: NCT03531242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Description: administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Description: administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63
Study: NCT05440240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous needle fasciotomy
Description: Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous needle fasciotomy
Description: Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Depo-Medrol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Isotonic saline
Study: NCT04788810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of d12-Cl2BPA
Description: Administration of d12-Cl2BPA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of d12-Cl2BPA
Description: Administration of d12-Cl2BPA
Study: NCT03824444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PODS
Description: Percutaneous Osseointegrated device for transhumeral patients
Study: NCT05403775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Description: 3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guidance
Description: The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
Study: NCT05807646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vein ligation first
Description: During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artery ligation first
Description: During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
Study: NCT05946512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga breathing techniques for dysfunctional breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social contact
Description: social contact as active comparator
Study: NCT06285123

Intervention type: BEHAVIORAL
Intervention: REP
Description: REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance.

Intervention type: BEHAVIORAL
Intervention: REP
Description: REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance.

Intervention type: BEHAVIORAL
Intervention: REP
Description: REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance.

Intervention type: BEHAVIORAL
Intervention: Facillitation
Description: Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
Study: NCT05950620

Intervention type: OTHER
Intervention: Medical obesity management.
Description: Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
Study: NCT05751148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaïne
Description: Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric prilocaïne
Description: Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
Study: NCT05135962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - rapid maxillary expansion
Description: Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with leaf expander
Description: Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with leaf expander
Description: Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with self leaf expander
Description: Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - slow maxillary expansion with self leaf expander
Description: Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
Study: NCT06334614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iReach
Description: The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
Study: NCT05011721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity tracker
Description: Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space.
Study: NCT05701566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality headset
Description: use of virtual reality headset during colonoscopy as a substitute to sedation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy with standard sedation.
Description: use of standard sedation during colonoscopy.
Study: NCT05487742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo salin infusion
Description: salin infused as aplacebo for 72 hours
Study: NCT06352255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital block
Description: Frost's H technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital block
Description: Frost's H technique
Study: NCT05606042

Intervention type: DEVICE
Intervention: IM Implant
Description: Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
Study: NCT05578287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-HER2 ADC
Description: Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
Study: NCT05954767

Intervention type: DRUG
Group type: OTHER
Intervention: IS-001
Description: IV injection of IS-001 drug substance with near infrared (NIR) imaging
Study: NCT06219395

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
Study: NCT06472713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection
Description: Mitoxantrone hydrochloride liposome injection once every 3 weeks for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
Study: NCT05776628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plenum® Tissue ortho membrane (polydioxanone membrane)
Description: Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
Study: NCT04731532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical respiratory physiotherapy with thoracic vibration
Description: Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical respiratory physiotherapy with thoracic vibration
Description: Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
Study: NCT05738720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)
Description: Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Programme
Description: Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test.
Study: NCT04941079

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00269815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate HCl
Study: NCT04814225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 1
Description: Pea Protein powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 2
Description: Pea \& Oat Protein Powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product 3
Description: Oat Protein Powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Whey Protein Isolate
Study: NCT05886296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.
Description: To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
Study: NCT05023226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RM
Description: RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPVS
Description: LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LPVS
Description: LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
Study: NCT05099562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.